TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies

The Lancet Oncology

Volumn 10, Issue 8, 2009, Pages 772-784

  Klug, Stefanie J ^a   Ressing, Meike ^a   Koenig, Jochem ^a   Abba, Martin C ^b   Agorastos, Theodoros ^c   Brenna, Sylvia MF ^d   Ciotti, Marco ^e   Das, BR ^f   Del Mistro, Annarosa ^g   Dybikowska, Aleksandra ^h   Giuliano, Anna R ⁱ   Gudleviciene, Zivile ^j   Gyllensten, Ulf ^k   Haws, Andrea LF ^l   Helland, Aslaug ^m   Herrington, C Simon ⁿ   Hildesheim, Alan ^o   Humbey, Olivier ^p   Jee, Sun H ^q   Kim, Jae Weon ^r   Madeleine, Margaret M ^s   Menczer, Joseph ^t   Ngan, Hextan YS ^u   Nishikawa, Akira ^v   Niwa, Yoshimitsu ^w   Pegoraro, Rosemary ^x   Pillai, MR ^y   Ranzani, Gulielmina ^z   Rezza, Giovanni ^aa   Rosenthal, Adam N ^ab   Roychoudhury, Susanta ^ac   Saranath, Dhananjaya ^ad   Schmitt, Virginia M ^ae   Sengupta, Sharmila ^af   Settheetham Ishida, Wannapa ^ag   Shirasawa, Hiroshi ^ah   Snijders, Peter JF ^ai   Stoler, Mark H ^aj   Suárez Rincón, Angel E ^ak   Szarka, Krisztina ^al   Tachezy, Ruth ^am   Ueda, Masatsugu ^an   van der Zee, Ate GJ ^ao   von Knebel Doeberitz, Magnus ^ap   Wu, Ming Tsang ^aq   Yamashita, Tsuyoshi ^ar   Zehbe, Ingeborg ^as   Blettner, Maria ^a   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d MASTERS AND DOCTORAL PROGRAMS IN PHYSICAL THERAPY   (Brazil)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f Super Religare Laboratories Ltd   (India)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j VILNIUS UNIVERSITY   (Lithuania)

^k UPPSALA UNIVERSITY   (Sweden)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ UNIVERSITY OF ST ANDREWS   (United Kingdom)

^o NATIONAL CANCER INSTITUTE   (United States)

^p UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^q Yonsei University   (South Korea)

^r Seoul National University   (South Korea)

^s Fred Hutchinson Cancer Research Center   (United States)

^t Gynecologic Oncology Unit   (Israel)

^u QUEEN MARY HOSPITAL   (Hong Kong)

^v Sapporo Medical Center   (Japan)

^w Niwa Clinic   (Japan)

^x UNIVERSITY OF KWAZULU NATAL   (South Africa)

^y RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^z UNIVERSITY OF PAVIA   (Italy)

^aa ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^ab UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ac INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^ad Reliance Life Science   (India)

^ae PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^af INDIAN STATISTICAL INSTITUTE   (India)

^ag KHON KAEN UNIVERSITY   (Thailand)

^ah CHIBA UNIVERSITY   (Japan)

^ai VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^aj UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^ak INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^al UNIVERSITY OF DEBRECEN   (Hungary)

^am INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^an Osaka Cancer Prevention and Detection Center   (Japan)

^ao UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ap UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^aq KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^ar Hakodate Municipal Hospital   (Japan)

^as Thunder Bay Regional Hospital   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ALLELE; ANALYTICAL ERROR; ARTICLE; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CODON; DATA ANALYSIS; EMBASE; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOCYTE; MEDLINE; METHODOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; SCISEARCH; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGED; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 67651158989     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70187-1     Document Type: Article

References (86)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No 5. Version 2.0 (2004), IARC press, Lyon
2. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
3. Munoz N., Bosch F.X., de Sanjose S., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52 (1992) 743-749
4. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
5. Plummer M., Herrero R., Franceschi S., et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14 (2003) 805-814
6. Appleby P., Beral V., Berrington de G.A., et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007) 1609-1621
7. International Collaboration of Epidemiological Studies of Cervical Cancer. comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 120 (2006) 885-891
8. Madeleine M.M., Johnson L.G., Smith A.G., et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 68 (2008) 3532-3539
9. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
10. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
11. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
12. Whibley C., Pharoah P.D., and Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 9 (2009) 95-107
13. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
14. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
15. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
16. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
17. Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
18. Agorastos T., Lambropoulos A.F., Constantinidis T.C., Kotsis A., and Bontis J.N. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 9 (2000) 113-118
19. Zehbe I., Voglino G., Wilander E., et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61 (2001) 608-611
20. Dokianakis D.N., and Spandidos D.A. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun 3 (2000) 111-114
21. Pegoraro R.J., Rom L., Lanning P.A., Moodley M., Naiker S., and Moodley J. p53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South Africa women. Int J Gynecol Cancer 12 (2002) 383-388
22. Klug S.J., Wilmotte R., Santos C., et al. TP53 polymorphism, HPV infection and cervical cancer. Cancer Epidemiol Biomarkers Prev 10 (2001) 1009-1012
23. Tachezy R., Mikyskova I., Salakova M., and Van Ranst M. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet 105 (1999) 564-566
24. Hildesheim A., Schiffman M., Brinton L.A., et al. p53 polymorphism and risk of cervical cancer. Nature 396 (1998) 531-532
25. Josefsson A.M., Magnusson P.K., Ylitalo N., et al. p53 polymorphism and risk of cervical cancer. Nature 396 (1998) 531
26. Madeleine M.M., Shera K., Schwartz S.M., et al. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 225-227
27. Koushik A., Platt R.W., and Franco E.L. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13 (2004) 11-22
28. Jee S.H., Won S.Y., Yun J.E., Lee J.E., Park J.S., and Ji S.S. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 85 (2004) 301-308
29. Hayes V.M., Hofstra R.M., Buys C.H., Hollema H., and van der Zee A.G. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 352 (1998) 1756
30. Egger M., Davey S.G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
31. Breslow N.E., and Day N.E. Statistical methods in cancer research. Vol I: the analysis of case-control studies. IARC Sci Publ No 32 edn (1980), IARC, Lyon
32. Thakkinstian A., McElduff P., D'Este C., Duffy D., and Attia J. A method for meta-analysis of molecular association studies. Stat Med 24 (2005) 1291-1306
33. Själander A., Birgander R., Saha N., Beckman L., and Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 46 (1996) 41-48
34. Inserra P., Abrahamsen M., Papenfuss M., and Giuliano A.R. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 14 (2003) 800-804
35. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. 2008.
36. Helland A., Langerod A., Johnsen H., Olsen A.O., Skovlund E., and Borresen-Dale A.L. p53 polymorphism and risk of cervical cancer. Nature 396 (1998) 530-531
37. Rosenthal A.N., Ryan A., Al-Jehani R.M., Storey A., Harwood C.A., and Jacobs I.J. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352 (1998) 871-872
38. Bertorelle R., Chieco-Bianchi L., and Del-Mistro A. Papillomavirus and p53 codon 72 polymorphism. Int J Cancer 82 (1999) 616-617
39. Giannoudis A., Graham D.A., Southern S.A., and Herrington C.S. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 83 (1999) 66-69
40. Klaes R., Ridder R., Schaefer U., Benner A., and von Knebel Doeberitz M. No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer. J Mol Med 77 (1999) 299-302
41. Ngan H.Y., Liu V.W., and Liu S.S. Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer 80 (1999) 1828-1829
42. Szarka K., Veress G., Konya J., and Gergely L. Frequency of p53 codon 72 genotypes in human papillomavirus associated squamous intraepithelial lesions and cervical cancer. Anticancer Res 19 (1999) 2377-2380
43. Yamashita T., Yaginuma Y., Saitoh Y., et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis 20 (1999) 1733-1736
44. Dybikowska A., Dettlaff A., Konopa K., and Podhajska A. p53 codon 72 polymorphism in cervical cancer patients and healthy women from Poland. Acta Biochimica Polonica 47 (2000) 1179-1182
45. Malcolm E.K., Baber G.B., Boyd J.C., and Stoler M.H. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol 13 (2000) 373-378
46. Nishikawa A., Fujimoto T., Akutagawa N., et al. p53 Polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 10 (2000) 402-427
47. Tenti P., Vesentini N., Rondo Spaudo M., et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 9 (2000) 435-438
48. Van Duin M., Snijders P.J., Vossen M.T.M., et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81 (2000) 317-325
49. Kim J.W., Roh J.W., Park N.H., Song Y.S., Kang S.B., and Lee H.P. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol 184 (2001) 55-58
50. Rezza G., Giuliani M., Garbuglia A.R., et al. Lack of association between p53 codon-72 polymorphism and squamous intraepithelial lesions in women with, or at risk for, human immunodeficiency virus and/or human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 10 (2001) 565-566
51. Arbel-Alon S., Menczer J., Feldman N., Glezerman M., Yeremin L., and Friedman E. Codon 72 polymorphism of p57 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 12 (2002) 741-744
52. Bhattacharya P., Duttagupta C., and Sengupta S. Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian women. Cancer Lett 188 (2002) 207-211
53. Humbey O., Aubin F., Cairey-Remonnay S., et al. TP53 polymorphism at exon 4 in caucasian women from eastern France: lack of correlation with HPV status and grade of cervical precancerous lesions. Eur J Obstet Gynecol Reprod Biol 103 (2002) 60-64
54. Kawamata Y., Mitsuhashi A., Unno Y., et al. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocyted. Int J Oncol 21 (2002) 561-567
55. Nagpal J.K., Sahni S., and Das B.R. p53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women. Eur J Clin Invest 32 (2002) 943-948
56. Pillai M.R., Sreevidya S., Pollock B.H., Jayaprakash P.G., and Herman B. Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. J Cancer Res Clin Oncol 128 (2002) 627-631
57. Saranath D., Khan Z., Tandle A.T., et al. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 86 (2002) 157-162
58. Suarez-Rincon A.E., Moran-Moguel M.C., Montoya-Fuentes H., Gallegos-Arreola M.P., and Sanchez-Corona J. Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico. Ginecol Obstet Mex 70 (2002) 344-348
59. Abba M., Villaverde L., Gomez M., Dulout F., Laguens M., and Golijow C. p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol 109 (2003) 63-66
60. Jee S.H., Lee J.E., and Park J.S. Polymorphism of codon 72 of p53 and environmental factors in the development of cervical cancer. Int J Gynaecol Obstet 80 (2003) 69-70
61. Brenna S.M., da Silva I., Zeferino L.C., Pereira J., Martinez E.Z., and Syrjanen K.J. Prevalence of codon 72 P53 polymorphism in Brazilian women with cervix cancer. Genet Mol Biol 27 (2004) 496-499
62. Niwa Y., Hamajima N., Atsuta Y., et al. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 205 (2004) 55-60
63. Settheetham-Ishida W., Singto Y., Yuenyao P., Tassaneeyakul W., Kanjanavirojkul N., and Ishida T. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett 210 (2004) 205-211
64. Wu M.T., Liu C.L., Ho C.K., and Wu T.N. Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. J Formos Med Assoc 103 (2004) 337-343
65. Haws A.L., Woeber S., Gomez M., et al. Human papillomavirus infection and P53 codon 72 genotypes in a Hispanic population at high-risk for cervical cancer. J Med Virol 77 (2005) 265-272
66. Mitra S., Misra C., Singh R.K., Panda C.K., and Roychoudhury S. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol 58 (2005) 26-31
67. Ueda M., Hung Y.C., Terai Y., et al. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis. Gynecol Oncol 96 (2005) 736-740
68. Ciotti M., Coletti A., Giuliani L., Cappiello G., Syrjanen K., and Favalli C. The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. Anticancer Res 26 (2006) 3745-3748
69. Gudleviciene Z., Didziapetriene J., Ramael M., Uleckiene S., and Valuckas K.P. Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol Oncol 102 (2006) 530-533
70. Ueda M., Terai Y., Kanda K., et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100 (2006) 173-178
71. Ioannidis J.P., Boffetta P., Little J., et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37 (2008) 120-132
72. Palmer T.M., Thompson J.R., and Tobin M.D. Meta-analysis of Mendelian randomization studies incorporating all three genotypes. Stat Med 27 (2008) 6570-6582
73. Kashima T., Makino K., Soemantri A., and Ishida T. TP53 codon 72 polymorphism in 12 populations of insular southeast Asia and Oceania. J Hum Genet 52 (2007) 694-697
74. Trikalinos T.A., Salanti G., Khoury M.J., and Ioannidis J.P. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 163 (2006) 300-309
75. Hosking L., Lumsden S., Lewis K., et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 12 (2004) 395-399
76. Yesupriya A., Evangelou E., Kavvoura F.K., et al. Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment. BMC Med Res Methodol 8 (2008) 31
77. Wild C.P., Vineis P., and Garte S. Molecular epidemiology of chronic diseases (2008), John Wiley and Son, West Sussex
78. Vineis P., and Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 16 (2007) 1954-1965
79. Lea I.A., Jackson M.A., Li X., Bailey S., Peddada S.D., and Dunnick J.K. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis 28 (2007) 1851-1858
80. Marin M.C., Jost C.A., Brooks L.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25 (2000) 47-54
81. Amira N., Mourah S., Rozet F., et al. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 101 (2002) 293-297
82. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18 (1999) 321-359
83. Orsted D.D., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204 (2007) 1295-1301
84. van Heemst D., Mooijaart S.P., Beekman M., et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40 (2005) 11-15
85. Makni H., Franco E.L., Kaiano J., et al. p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 87 (2000) 528-533
86. Dwan K., Altman D.G., Arnaiz J.A., et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3 (2008) e3081